Baker Bros. Advisors LP Neurocrine Biosciences Inc Transaction History

Baker Bros. Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $51.3 Million - $67.7 Million	-676,975 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $22.1 Million - $31.1 Million	-230,011 Reduced 25.36%	676,975 $65.1 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $28.4 Million - $43.4 Million	-333,257 Reduced 26.87%	906,986 $111 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.05 Million - $1.59 Million	-14,000 Reduced 1.12%	1,240,243 $107 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $14 Million - $19.1 Million	-161,040 Reduced 11.38%	1,254,243 $135 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $22.9 Million - $28.9 Million	316,613 Added 28.82%	1,415,283 $119 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $25.5 Million - $33.7 Million	368,315 Added 50.43%	1,098,670 $96.8 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $14.6 Million - $26.6 Million	-214,269 Reduced 22.68%	730,355 $52.2 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $4.55 Million - $5.55 Million	-60,000 Reduced 5.97%	944,624 $78.3 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $22.7 Million - $30.1 Million	387,942 Added 62.91%	1,004,624 $77.9 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $29.6 Million - $37.8 Million	616,682	616,682 $37.8 Million

656

95.3M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $9.08B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.